ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BIVI BioVie Inc

0.51
0.0182 (3.70%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 878,438
Bid Price 0.49
Ask Price 0.5123
News -
Day High 0.524

Low
0.445

52 Week Range

High
8.69

Day Low 0.48
Company Name Stock Ticker Symbol Market Type
BioVie Inc BIVI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0182 3.70% 0.51 19:54:28
Open Price Low Price High Price Close Price Prev Close
0.50 0.48 0.524 0.5054 0.4918
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,825 878,438 $ 0.5035802 $ 442,364 - 0.445 - 8.69
Last Trade Time Type Quantity Stock Price Currency
19:54:27 formt 296 $ 0.51 USD

BioVie Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
20.33M 39.87M - 0 -50.26M -1.26 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

BioVie News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BIVI Message Board. Create One! See More Posts on BIVI Message Board See More Message Board Posts

Historical BIVI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.49750.5240.45210.4853032733,7780.01252.51%
1 Month0.5450.5610.4450.4992196908,943-0.035-6.42%
3 Months1.043.310.4451.412,768,000-0.53-50.96%
6 Months3.545.820.4451.701,705,609-3.03-85.59%
1 Year7.838.690.4452.05962,222-7.32-93.49%
3 Years18.7523.860.4453.82507,601-18.24-97.28%
5 Years10.5046.09770.4454.32434,855-9.99-95.14%

BioVie Description

BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Your Recent History

Delayed Upgrade Clock